Stockscreener 앱 받기
15.80
0.13%
-0.02
시간 외 거래:
15.80
전일 마감가:
$15.82
열려 있는:
$15.73
하루 거래량:
505.29K
Relative Volume:
0.83
시가총액:
$448.73M
수익:
$320.35M
순이익/손실:
$-75.01M
주가수익비율:
-6.5963
EPS:
-2.3953
순현금흐름:
$-113.17M
1주 성능:
+6.04%
1개월 성능:
+9.49%
6개월 성능:
-45.67%
1년 성능:
-21.47%
1일 변동 폭
$15.62
$16.05
1주일 범위
$14.77
$16.18
52주 변동 폭
$13.46
$31.04
Fulgent Genetics Inc Stock (FLGT) Company Profile
명칭
Fulgent Genetics Inc
전화
626-350-0537
주소
4399 SANTA ANITA AVE, EL MONTE
Compare FLGT vs TMO, DHR, IDXX, WAT, A
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FLGT
Fulgent Genetics Inc
|
15.80 | 449.30M | 320.35M | -75.01M | -113.17M | -2.3953 |
TMO
Thermo Fisher Scientific Inc
|
459.30 | 168.20B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
166.26 | 117.86B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
533.92 | 41.97B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
352.21 | 34.17B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
112.90 | 31.50B | 7.07B | 1.29B | 993.00M | 4.5355 |
Fulgent Genetics Inc Stock (FLGT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-05 | 업그레이드 | UBS | Neutral → Buy |
| 2023-12-07 | 개시 | UBS | Neutral |
| 2022-12-08 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-11-18 | 개시 | Raymond James | Outperform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-02-04 | 재개 | Piper Sandler | Overweight |
| 2021-08-05 | 재개 | Credit Suisse | Underperform |
| 2021-01-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2020-11-24 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-08-20 | 개시 | Oppenheimer | Outperform |
| 2020-05-29 | 개시 | BTIG Research | Buy |
| 2019-11-05 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-03-01 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-11-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
모두보기
Fulgent Genetics Inc 주식(FLGT)의 최신 뉴스
Fulgent Genetics infertility test panels broaden to cover over 140 genes for females and 160 for males - Traders Union
LA500 2026: Ming Hsieh - Los Angeles Business Journal
Fulgent Genetics (NASDAQ:FLGT) Stock Passes Below Fifty Day Moving AverageHere's Why - MarketBeat
Fulgent Genetics (NASDAQ:FLGT) Stock Rating Lowered by Wall Street Zen - MarketBeat
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm - The Globe and Mail
Number of shareholders of Fulgent Genetics, Inc. – NASDAQ:FLGT - TradingView
Fulgent (FLGT) Q1 2026 Earnings Transcript - AOL.com
SEC EDGAR Submission 0000950170-25-062257 - SEC.gov
Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics - BioSpace
PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics - Business Wire
Fulgent Genetics, Inc. (NASDAQ:FLGT) Q1 2026 Earnings Call Transcript - Insider Monkey
Fulgent Q1 2026 slides: revenue misses amid customer loss, therapy data shines - Investing.com Nigeria
Fulgent Genetics (FLGT) Trailing US$60 Million Loss Tests Bullish Margin Narratives - Sahm
Fulgent Genetics Inc (FLGT) Q1 2026 Earnings Call Highlights: Na - GuruFocus
Understanding the Setup: (FLGT) and Scalable Risk - Stock Traders Daily
Fulgent Genetics, Inc. Q1 2026 SEC 10-Q Filing: Financial Statements, Company Information, and Risk Disclosure - Minichart
Fulgent Genetics Reports Q1 2026 Results: $71M Revenue, Stock Buyback, Updated Guidance and Progress in Cancer Therapeutics - Minichart
Fulgent Genetics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Is Fulgent Genetics (FLGT) 38.5% Undervalued After Q1 2026? Reve - GuruFocus
Fulgent outlines $350M 2026 revenue outlook following Bako/StrataDx acquisition - MSN
Fulgent Genetics, Inc. (FLGT) reports Q1 loss, beats revenue estimates - MSN
Fulgent Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Fulgent Genetics Posts Q1 Loss, Reaffirms 2026 Outlook - TipRanks
Fulgent Genetics 1Q 2026: Revenue $71.1M, Net loss $(24.8)M, EPS $(0.80) — 10-Q Summary - TradingView
Fulgent Genetics Q1 Earnings Call Highlights - MarketBeat
Earnings call transcript: Fulgent Genetics disappoints with Q1 2026 results By Investing.com - Investing.com South Africa
Fulgent Reports First Quarter 2026 Financial Results - The National Law Review
Fulgent Genetics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Fulgent Genetics disappoints with Q1 2026 results - Investing.com
Full Transcript: Fulgent Genetics Q1 2026 Earnings Call - Benzinga
Fulgent Genetics (NASDAQ:FLGT) Shares Dip Premarket After Q1 Earnings Miss Despite Revenue Beat - ChartMill
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Fulgent Genetics (NASDAQ:FLGT) Releases FY 2026 Earnings Guidance - MarketBeat
FLGT: Q1 2026 revenue fell 3% YoY, but growth in drug development and acquisitions support a $350M 2026 outlook - TradingView
FULGENT GENETICS ($FLGT) Releases Q1 2026 Earnings - Quiver Quantitative
[10-Q] Fulgent Genetics, Inc. Quarterly Earnings Report - Stock Titan
Fulgent Genetics Sees 2026 Adj Loss/Shr $1.59 >FLGT - Moomoo
Fulgent Genetics (NASDAQ: FLGT) posts Q1 2026 loss, reaffirms $350M revenue outlook - Stock Titan
Fulgent Genetics Q1 2026 earnings preview - MSN
Fulgent Genetics Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Fulgent Genetics (FLGT) CSO has 1,645 shares withheld for tax obligations - Stock Titan
Fulgent Genetics (FLGT) COO reports tax-withholding share disposition after RSU vesting - Stock Titan
Fulgent Genetics (FLGT) CFO has 2,747 shares withheld for RSU taxes - Stock Titan
Fulgent Reports Second Quarter 2024 Financial Results - 富途牛牛
Fulgent Genetics rises on earnings, revenue beat - MSN
Fulgent Genetics (FLGT) to Release Earnings on Friday - MarketBeat
Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting - BioSpace
Fulgent Genetics, Inc. (NASDAQ:FLGT) Given Average Rating of "Hold" by Analysts - MarketBeat
Fulgent Genetics to present nano-encapsulated anti-tumor drug FID-007 efficacy at ASCO meeting - Traders Union
Head and neck cancer study from Fulgent gets ASCO oral slot - Stock Titan
Fulgent Genetics Inc (FLGT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.89%
0.56%
자본화:
|
볼륨(24시간):